歐洲聲音/語音生物標記市場：按平台類型、適應症、應用類型、最終用戶和國家分類的分析與預測（2025年至2035年）

歐洲聲音/語音生物標記市場預計將從2024年的3.352億美元成長到2035年的16.997億美元，在2025-2035年預測期內的年複合成長率為 16.0%。

歐洲開發和使用聲音或語音生物標記來識別、追蹤和預測健康問題。這些生物標記是基於人類聲音的特徵。作為數位生物標記的子集，它們使用可量化的聲音特徵，例如音高、音調、頻率、振幅、語速和顫抖。這些特徵代表生理和病理狀況，實現非侵入性診斷和持續的健康監測。

軟體平台、硬體輔助診斷工具和整合遠距遠端保健解決方案用於分析語音資料以進行早期疾病檢測，特別是神經、精神、呼吸、心血管和認知疾病，都是歐洲語音生物標記市場的一部分，不僅應用於臨床環境，還應用於健康、職業健康、認知表現和防禦。

歐洲市場的成長受到人工智慧的進步、遠距醫療基礎設施的擴大以及與傳統診斷方法相比對具有成本效益、可擴展和快速篩檢工具的需求的推動。

市場介紹

歐洲聲音/語音生物標記市場是數位健康生態系統中的新興市場，該生態系統利用人類聲音特徵作為可量化的生物指標來識別、追蹤和預測疾病。這些生物標記會偵測音高、音調、頻率、振幅、語速和顫抖等聲音特徵，這些特徵可能預示著潛在的生理或病理狀況。語音生物標記能夠實現非侵入式即時監測，被定位為遠端病患管理、早期疾病檢測和個人化醫療的突破性工具。

在歐洲，市場涵蓋軟體平台、人工智慧主導的診斷解決方案和硬體輔助工具，在臨床和居家照護環境中的應用日益廣泛。語音分析可以提供持續、經濟實惠且患者友善的監測選項，隨著人們對神經系統疾病、心理健康問題和慢性疾病的了解不斷增加，語音分析也越來越受到關注。此外，機器學習（ML）與人工智慧（AI）的整合可以提高預測準確性，並實現在不同人群中的可擴展部署。

研究機構、技術開發商、數位健康新興企業和醫療保健提供者是支持語音診斷快速發展的關鍵參與者。歐洲法規結構不斷發展，以促進這些數位生物標記物的使用，同時維護資料隱私並符合醫療設備標準。隨著市場的發展，歐洲預計將成為語音生物標記物創新的中心，重點關注個人化醫療和有效的醫療保健服務。

市場區隔

細分1：依平台類型

• 雲端基礎
• 基於網路

細分2：依適應症類型

• 神經系統疾病
• 精神疾病
• 呼吸系統疾病
• 心血管疾病
• 其他

細分 3：依應用類型

• 診斷
• 監控
• 臨床研究
• 其他

細分 4：依最終用戶

• 醫院
• CRO
• 研究所

細分5：依地區

• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他

歐洲聲音/語音生物標記市場趨勢、促進因素與挑戰

市場趨勢

• 人工智慧和機器學習的融合度不斷提高，用於基於語音的情緒、壓力和疾病檢測。
• 數位生物標記在臨床試驗和藥物開發的應用越來越多，特別是針對神經和精神疾病。
• 遠端醫療和遠端監控平台的擴展以及即時語音分析的採用增加。
• 一家健康科技公司和一家製藥公司合作開發語音診斷工具。
• 利用語音生物標記進行早期疾病預測和病人參與行動醫療應用的興起。

關鍵市場促進因素

• 神經退化性疾病（如帕金森氏症、憂鬱症、阿茲海默症）的盛行率不斷上升。
• 歐洲數位健康創新的監管靈活性（歐盟 MDR 與基於人工智慧的醫療工具的一致性）。
• 穿戴式裝置和智慧型手機的使用日益增多，將增強語音資料收集的途徑。
• 對個人化醫療和非侵入性、持續監測解決方案的需求不斷成長。
• 增加臨床生物標記研究的研發投入和政府資助。

市場挑戰

• 缺乏針對語音生物標記的準確性和可重複性的標準化檢驗框架。
• 醫療系統和消費者應用之間的資料隱私和互通性問題。
• 歐洲各國針對數位和語音診斷的償付模式不透明。
• 人工智慧模型開發和臨床試驗的資本成本高昂，且缺乏熟練的專家。
• 監管複雜性延遲了基於人工智慧和語音診斷解決方案的核准。

產品/創新策略：本報告深入探討了聲音/語音生物標記的最新技術進步，使公司能夠推動創新並開發出滿足市場需求的尖端產品。

成長/行銷策略：透過提供全面的市場分析和識別關鍵的成長機會，公司能夠獲得制定有針對性的行銷策略和有效擴大其市場佔有率的知識。

競爭策略：本報告包括全面的競爭格局分析，以了解語音/聲音生物標記市場中競爭對手的優勢和劣勢，並制定有效的策略以在市場上獲得競爭優勢。

監管與合規策略：提供有關聲音/聲音生物標記的法律規範、核准和行業指南的最新資訊，使公司能夠保持合規並加速新聲音/聲音生物標記的市場進入。

投資和業務擴大策略：透過分析市場趨勢、資金籌措模式和合作機會，幫助公司做出明智的投資決策並確定業務成長的潛在併購機會。

主要市場參與企業和競爭對手的摘要

公司簡介是根據從主要專家收集的意見以及對公司覆蓋範圍、產品系列和市場滲透率的分析而選擇的。

市場上一些值得注意的參與者包括：

• auddering GmbH
• EVOCAL Health GmbH
• VoiceMed Italia Srl
• Zana Technologies GmbH

目錄

執行摘要

第1章 歐洲語音生物標記市場：產業展望

• 產業展望
  • 市場概況與生態系統
  • 競爭力評估
  • 機會評估
  • 資金籌措分析
• 市場動態
  • 趨勢、促進因素、挑戰和機會：評估當前和未來的影響
• 趨勢
  • 將AI/ML整合到語音生物標記技術中
  • 市場促進因素
  • 市場限制
  • 市場機會
  • 市場挑戰

第2章 區域

• 歐洲
  • 區域概況
  • 市場成長動力
  • 成長抑制因素
  • 市場規模及預測
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 其他

第3章 競爭格局與公司概況

• 公司簡介
  • audEERING GmbH
  • EVOCAL Health GmbH
  • VoiceMed Italia srl
  • Zana Technologies GmbH

第4章 調查方法

This report can be delivered in 2 working days.

Introduction to Europe Voice/Vocal Biomarker Market

The Europe voice/vocal biomarker market is projected to reach $1,699.7 million by 2035 from $335.2 million in 2024, growing at a CAGR of 16.0% during the forecast period 2025-2035. Vocal or voice biomarkers are developed and used in Europe to identify, track, and forecast health issues. These biomarkers are based on the features of human voices. They use quantifiable voice characteristics, such as pitch, tone, frequency, amplitude, speech rate, and tremor, as a subset of digital biomarkers. These characteristics represent physiological and pathological states and allow for non-invasive diagnoses and ongoing health monitoring.

Software platforms, hardware-assisted diagnostic tools, and telehealth-integrated solutions that analyze voice data for early disease detection-particularly in neurological, mental health, respiratory, cardiovascular, and cognitive disorders-are all part of the European voice biomarker market. Beyond clinical use, applications extend to wellness, occupational health, cognitive performance, and defense sectors.

Market growth in Europe is propelled by advances in AI, expanding remote healthcare infrastructure, and the demand for cost-effective, scalable, and rapid screening tools compared to conventional diagnostic methods.

Market Introduction

An emerging market within the larger digital health ecosystem is the European voice and vocal biomarker market, which uses the features of human voices as quantifiable biological indicators to identify, track, and forecast medical disorders. These biomarkers examine vocal characteristics that may indicate underlying physiological or pathological conditions, including pitch, tone, frequency, amplitude, speech pace, and tremor. Voice biomarkers are positioned as a game-changing tool for remote patient management, early illness identification, and personalized healthcare by facilitating non-invasive, real-time monitoring.

In Europe, the market spans software platforms, AI-driven diagnostic solutions, and hardware-assisted tools, with increasing adoption across clinical and home-care settings. Voice analysis can offer continuous, affordable, and patient-friendly monitoring options, which is generating interest as knowledge of neurological problems, mental health issues, and chronic diseases grows. Additionally, integrating machine learning (ML) and artificial intelligence (AI) improves prediction accuracy and permits scalable deployment across a range of demographics.

Research institutes, technology developers, digital health startups, and healthcare providers are important players who support the quick development of speech-based diagnostics. While maintaining data privacy and adherence to medical device standards, European regulatory frameworks are changing to facilitate the use of these digital biomarkers. Europe is anticipated to develop as a center for voice biomarker innovation as the market evolves, with a focus on individualized medication and effective healthcare delivery.

Market Segmentation:

Segmentation 1: By Platform Type

• Cloud-based
• Web-based

Segmentation 2: By Indication Type

• Neurological Disorder
• Mental Health Disorder
• Respiratory Diseases
• Cardiovascular Disease
• Others

Segmentation 3: By Application Type

• Diagnostics
• Monitoring
• Clinical Research
• Others

Segmentation 4: By End User

• Hospitals
• CROs
• Research Institutions

Segmentation 5: By Region

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe

Europe Voice/Vocal Biomarker Market Trends, Drivers & Challenges

Market Trends

• Increasing integration of AI and machine learning for voice-based emotion, stress, and disease detection.
• Growing adoption of digital biomarkers in clinical trials and drug development, especially for neurological and psychiatric disorders.
• Expansion of telehealth and remote monitoring platforms, driving real-time voice analytics adoption.
• Partnerships between health-tech firms and pharmaceutical companies to develop voice-enabled diagnostic tools.
• Rise of mobile health apps leveraging vocal biomarkers for early disease prediction and patient engagement.

Key Market Drivers

• Rising prevalence of neurodegenerative and mental health disorders (e.g., Parkinson's, depression, Alzheimer's).
• Regulatory flexibility toward digital health innovations in Europe (EU MDR alignment with AI-based medical tools).
• Increasing use of wearable devices and smartphones enhancing access to voice-data collection.
• Growth in personalized medicine and demand for non-invasive, continuous monitoring solutions.
• Increasing R&D investments and government funding for clinical biomarker research.

Market Challenges

• Lack of standardized validation frameworks for voice biomarker accuracy and reproducibility.
• Data privacy and interoperability issues between medical systems and consumer applications.
• Uncertain reimbursement models for digital and voice-based diagnostics across European nations.
• High capital costs and shortage of skilled professionals for AI model development and clinical testing.
• Regulatory complexity delaying approval of AI-based and vocal-diagnostic solutions.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in voice/vocal biomarker, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses in Voice/Vocal Biomarker and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines specific to Voice/Vocal Biomarker, ensuring organizations stay compliant and accelerate market entry for new voice/vocal biomarker

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in the market are:

• auddering GmbH
• EVOCAL Health GmbH
• VoiceMed Italia Srl
• Zana Technologies GmbH

Table of Contents

Executive Summary

Scope and Definition

1 Europe Voice/Vocal Biomarker Market: Industry Outlook

• 1.1 Industry Outlook
  • 1.1.1 Market Overview and Ecosystem
    • 1.1.1.1 Future Direction and Emerging Technology
  • 1.1.2 Competitive Assessment
    • 1.1.2.1 Go-to-Market Strategy
    • 1.1.2.2 Competitive Landscape
      • 1.1.2.2.1 Business Strategies
  • 1.1.3 Opportunity Assessment
    • 1.1.3.1 Strategic Opportunities of Stakeholders in Voice/Vocal Biomarker Market
    • 1.1.3.2 Market Opportunity and Demand Analysis
  • 1.1.4 Funding Analysis
• 1.2 Market Dynamics
  • 1.2.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
• 1.3 Trends
  • 1.3.1 Integration of AI/ML into Vocal Biomarker Technologies
  • 1.3.2 Market Drivers
    • 1.3.2.1 Rising Application of Vocal Biomarkers as Novel Diagnostic and Monitoring Aid
    • 1.3.2.2 Increasing Demand for Remote and Non-Invasive Health Monitoring
    • 1.3.2.3 Adoption of Vocal Biomarkers in Health and Wellness Apps
  • 1.3.3 Market Restraints
    • 1.3.3.1 Regulatory Challenges and Unclear Guidelines
      • 1.3.3.1.1 Regulatory Approval for AI/ML-based Vocal Biomarker Applications
      • 1.3.3.1.2 Need for Clinical Validation
    • 1.3.3.2 Integration of Vocal Biomarker Technologies in Healthcare Systems and Associated Complexities
      • 1.3.3.2.1 Integration with EHR
      • 1.3.3.2.2 Integration with Telehealth Platforms
      • 1.3.3.2.3 Integration with Wearables and Smart Devices
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Early Disease Detection and Prevention using Vocal Biomarkers
    • 1.3.4.2 Increasing Number of Clinical Trials and Research on Vocal Biomarker
  • 1.3.5 Market Challenges
    • 1.3.5.1 Technology Limitations and Accuracy Issues
    • 1.3.5.2 Lack of Standardized Regulations on Vocal Biomarker

2 Region

• 2.1 Europe
  • 2.1.1 Regional Overview
  • 2.1.2 Driving Factors for Market Growth
  • 2.1.3 Factors Challenging the Market
  • 2.1.4 Market Sizing and Forecast
    • 2.1.4.1 Europe Voice/Vocal Biomarkers Market, by Platform Type
    • 2.1.4.2 Europe Voice/Vocal Biomarkers Market, by Application
    • 2.1.4.3 Europe Voice/Vocal Biomarkers Market, by Indication
    • 2.1.4.4 Europe Voice/Vocal Biomarkers Market, by End User
    • 2.1.4.5 Europe Voice/Vocal Biomarkers Market, by Country
  • 2.1.5 U.K.
    • 2.1.5.1 Country Overview
      • 2.1.5.1.1 Market Sizing and Forecast
  • 2.1.6 Germany
    • 2.1.6.1 Country Overview
      • 2.1.6.1.1 Market Sizing and Forecast
  • 2.1.7 France
    • 2.1.7.1 Country Overview
      • 2.1.7.1.1 Market Sizing and Forecast
  • 2.1.8 Italy
    • 2.1.8.1 Country Overview
      • 2.1.8.1.1 Market Sizing and Forecast
  • 2.1.9 Spain
    • 2.1.9.1 Country Overview
      • 2.1.9.1.1 Market Sizing and Forecast
  • 2.1.10 Rest-of-the- Europe
    • 2.1.10.1 Country Overview
      • 2.1.10.1.1 Market Sizing and Forecast

3 Competitive Landscape and Company Profiles

• 3.1 Company Profiles
  • 3.1.1 audEERING GmbH
    • 3.1.1.1 Overview
  • 3.1.2 EVOCAL Health GmbH
    • 3.1.2.1 Overview
  • 3.1.3 VoiceMed Italia srl
    • 3.1.3.1 Overview
  • 3.1.4 Zana Technologies GmbH
    • 3.1.4.1 Overview

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Inclusion and Exclusion
  • 4.1.4 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Voice/Vocal Biomarker Market (by Scenario), $Million, 2024, 2028, and 2035
• Figure 2: Europe Voice/Vocal Biomarker Market, 2024-2035
• Figure 3: Europe Voice/Vocal Biomarker Market Snapshot
• Figure 4: Voice/Vocal Biomarker Market, $Million, 2024 and 2035
• Figure 5: Europe Voice/Vocal Biomarker Market (by Platform Type), $Million, 2024, 2028, and 2035
• Figure 6: Europe Voice/Vocal Biomarker Market (by Application Type), $Million, 2024, 2028, and 2035
• Figure 7: Europe Voice/Vocal Biomarker Market (by Indication Type), $Million, 2024, 2028, and 2035
• Figure 8: Europe Voice/Vocal Biomarker Market (by End User), $Million, 2024, 2028, and 2035
• Figure 9: Europe Voice/Vocal Biomarker Market Segmentation
• Figure 10: Go-to-Market Strategy of Major Players
• Figure 11: Go-to-Market Strategy of Major Players
• Figure 12: Go-to-Market Strategy of Major Players
• Figure 13: Companies Offering AI-based Vocal Biomarkers for Early Disease Detection
• Figure 14: Europe Voice/Vocal Biomarkers Market, $Million, 2024-2035
• Figure 15: U.K. Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 16: Germany Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 17: France Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 18: Italy Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 19: Spain Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 20: Rest-of-the Europe Voice/Vocal BIomarkers Market, $Million, 2024-2035
• Figure 21: Inclusion and Exclusion Criteria for Europe Voice/Vocal Biomarker Market
• Figure 22: Data Triangulation
• Figure 23: Top-Down and Bottom-Up Approach
• Figure 24: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Recent Funding in Europe Voice/Vocal Biomarker Market
• Table 3: Use of AI/ML Technology by Companies
• Table 4: Key Market Players and their Major Contributions
• Table 5: Few Clinical Trials Related to Voice Biomarker
• Table 6: Voice/Vocal Biomarkers Market (by Region), $Million, 2024-2035
• Table 7: Europe Voice/Vocal Biomarkers Market (by Platform Type), $Million, 2024-2035
• Table 8: Europe Voice/Vocal Biomarkers Market (by Application), $Million, 2024-2035
• Table 9: Europe Voice/Vocal Biomarkers Market (by Indication), $Million, 2024-2035
• Table 10: Europe Voice/Vocal Biomarkers Market (by End User), $Million, 2024-2035
• Table 11: Europe Voice/Vocal Biomarkers Market (by Country), $Million, 2024-2035